Yazar "Paydaş, Semra" için listeleme
-
Assessment of prognostic factors and adjuvant treatment modalities in adult head and neck soft tissue sarcoma patients treated with upfront surgery
Akagündüz, Baran; Akın Telli, Tuğba; Göksu, Sema Sezgin; Yıldırım, Hasan Çağrı; Özer, Muhammet; Göktaş Aydın, Sabin; Özyurt, Neslihan; Karacin, Cengiz; Paydaş, Semra; Doğan, Mutlu (Cureus Inc., 2021)Objectives Head and neck soft tissue sarcomas (HNSTSs) are a heterogeneous group of rare tumors. Surgical resection with negative margins remains the standard primary treatment for patients with HNSTS. The role of ... -
Factors affecting survival in retroperitoneal sarcomas treated with upfront surgery: A real-world study by Turkish Oncology Group
Akagündüz, Baran; Akın Telli, Tuğba; Yıldırım, Hasan Çağrı; Göksu, Sema Sezgin; Demir, Nazan; Hafızoğlu, Emre; Özer, Muhammet; Çevik, Gökçen Tuğba; Sakin, Abdullah; Göktaş Aydın, Sabin; Şengül Samancı, Nilay; Özyurt, Neslihan; Atçı, Muhammed Mustafa; Ayhan, Murat; Turan, Merve; Sarıyar, Nisanur; Karaçin, Cengiz; Kılıçkap, Saadettin; Paydaş, Semra; Doğan, Mutlu (Akad Doktorlar Yayınevi, 2021)Retroperitoneal sarcomas (RPS) account for approximately 15% of all soft tissue sarcomas (STS) and encompass a heterogeneous group of tumors with limited multimodality treatment options. Surgical resection with negative ... -
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study
Özyurt, Neslihan; Alkan, Ali; Gülbağcı, Burcu; Seyyar, Mustafa; Aydın, Esra; Şahbazlar, Mustafa; Türker, Mehmet; Kınıkoğlu, Oğuzcan; Yerlikaya, Tahir; Dinç, Gülhan; Aytaç, Ali; Kalkan, Ziya; Ebinç, Senar; Gültürk, İlkay; Keskinkılıç, Merve; İşleyen, Zehra Sucuoğlu; Çağlayan, Dilek; Türkel, Alper; Şakalar, Teoman; Sekmek, Serhat; Yıldırım, Nilgün; Koçak, Sinem; Okutur, Kerem; Özveren, Ahmet; Dursun, Bengü; Kitaplı, Sait; Eren, Orhan Önder; Beypınar, İsmail; Hacıbekiroğlu, İlhan; Çabuk, Devrim; Karaman, Elanur; Acar, Ömer; Paydaş, Semra; Eryılmaz, Melek Karakurt; Demir, Bilgin; Oruç, Zeynep; Yılmaz, Mesut; Biricik, Fatih Selçuk; Salim, Derya Kıvrak; Tanrıverdi, Özgür; Doğan, Mutlu (Nature Research, 2024)The studies evaluating the impact of Her2 levels in neoadjuvant setting have conflicting data. The aim of the study was to evaluate the prognostic impact of Her2 status in early triple negative breast cancer(TNBC). In the ... -
Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish oncology group (TOG) study
Kahraman, Seda; Erul, Enes; Gümüşay, Özge; Güven, Deniz Can; Aksoy, Sercan; Başaran, Gül; Seyyar, Mustafa; Şahin, Elif; Çabuk, Devrim; Bayram, Ertuğrul; Paydaş, Semra; Demirel, Burçin Çakan; Yaren, Arzu; Gülbağcı, Burcu; Hacıbekiroğlu, İlhan; Baytemur, Naziyet Köse; Demirci, Umut; Davarcı, Sena Ece; Demir, Hacer; Mocan, Eda Eylemer; Doğan, Özlem; Çılbır, Ebru; Yaşar, Alper; Bayoğlu, İbrahim Vedat; Hızal, Mutlu; Kayıkcıoğlu, Erkan; Çetin, Bülent; Acar, Ömer; Erdoğan, Atike Pınar; Keskinkılıç, Merve; Yavuzşen, Tuğba; Ünal, Olcun Ümit; Yılmaz, Funda; Doğan, Mutlu; Orhan, Sibel Oyucu; Çubukcu, Erdem; Erol, Cihan; Sakalar, Teoman; Dulgar, Özgecan; Karakaş, Yusuf; Özkanlı, Gülhan; Duman, Berna Bozkurt; Isık, Deniz; Karaoğlanoğlu, Müge; Okutur, Sadi Kerem; Yıldırım, Nilgün; Aydın, Esra; Uluç, Başak Oyan; Keser, Murat; Bilgin, Burak; Aksoy, Asude; Eren, Önder; Kalkan, Nurhan Önal; Er, Muhammed Muhiddin; Yücel, Hakan; Sunar, Veli; Paksoy, Nail; Aydın, Dinçer; Turhal, Nazım Serdar; Menekşe, Serkan (Elsevier, 2025)Background: Real-world (RW) data provide valuable information about the effectiveness and safety of treatment modalities in the general population that is not limited by selection criteria in clinical studies. The aim of ... -
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
Kahraman, Seda; Erul, Enes; Seyyar, Mustafa; Gümüşay, Özge; Bayram, Ertuğrul; Demirel, Burçin Çakan; Acar, Ömer; Aksoy, Sercan; Baytemur, Nazife Köse; Şahin, Elif; Çabuk, Devrim; Başaran, Gül; Paydaş, Semra; Yaren, Arzu; Güven, Deniz Can; Erdoğan, Atike Pınar; Demirci, Umut; Yaşar, Alper; Bayoğlu, İbrahim Vedat; Hızal, Mutlu; Gülbağcı, Mutlu; Paksoy, Nail; Davarcı, Sena Ece; Yılmaz, Funda; Doğan, Özlem; Orhan, Sibel Oyucu; Kayıkcıoğlu, Erkan; Aytaç, Ali; Keskinkılıç, Merve; Moçan, Eda Eylemer; Ünal, Ölçün Ümit; Aydın,Esra; Yücel, Hakan; Işık, Deniz; Eren, Önder; Uluç, Başak Oyan; Özçelik, Melike; Hacıbekiroğlu, İlhan; Aydıner, Adnan; Demir, Hacer; Öksüzoğlu, Berna; Çılbır, Ebru; Çubukçu, Erdem; Çetin, Bülent; Oktay, Esin; Erol, Cihan; Okutur, Sadi Kerem; Yıldırım, Nilgün; Alkan, Ali; Selçukbiricik, Fatih; Aksoy, Asude; Karakaş, Yusuf; Özkanlı, Gülhan; Duman, Berna Bozkurt; Aydın, Dinçer; Dulgar, Özgecan; Er, Muhammed Muhiddin; Teker, Fatih; Yavuzsen, Tuğba; Aykan, Musa Barış; İnal, Ali; İriağaç, Yakup; Kalkan, Nurhan Önal; Keser, Murat; Sakalar, Teoman; Menekşe, Serkan; Kut, Engin; Bilgin, Burak; Karaoğlanoğlu, Müge; Sunar, Veli; Özdemir, Özlem; Turhal, Nazım Serdar; Karadurmuş, Nuri; Yalçın, Bülent; Şendur, Mehmet Ali Nahit (Future Medicine Ltd, 2023)Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative ...
